Stanford scientists have developed a set of preclinical assays that are specifically designed to detect empathogenic effects of a drug that may indicate applications for that molecule in treating psychiatric diseases like PTSD.
Stanford scientists have invented a new suite of adaptable hydrogel biomaterials that are optically transparent and injectable for cell encapsulation, tissue engineering, and drug delivery.
The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
Stanford inventors in the lab of Dr. Katrin Svensson have discovered an endogenous peptide hormone that shows promise in treating obesity and diabetes.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford scientists have developed a neuroprotective, adeno-associated virus (AAV) gene therapy vector that expresses a mutant form of HDAC4 or a fragment of HDAC4 with novel applications to retinal and neurologic diseases, including glaucoma and other retinal ganglion cell di
Stanford researchers from the Khuri-Yakub group have designed an improved, high spatial resolution ultrasonic neuromodulation device that implements chip waveform instead of continuous wave PIRF.
Stanford inventors have developed a multiomic methodology for identifying and measuring non-structural proteins and RNA species from human hair. This approach will reveal unique biomarker profiles for wellness or diseases that are not currently identified.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Researchers in the Wyss-Coray Lab are investigating a potential therapeutic antibody to treat lysosomal storage disorders and other related neurodegenerative diseases.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Stanford inventors have engineered an adeno-associated virus (AAV) variant on the existing LK03 platform that enables this highly efficient primate-specific serotype for use in rodent preclinical studies.